Mepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two years.

Canonica GW, Bagnasco D, Lee JK, Chupp G, Schleich F, Oppenheimer JJ, Zhang L, Alfonso-Cristancho R, Howarth P.

Open source

DOI: 10.1183/23120541.01390-2024
Published: 2025-11-10
Container: ERJ Open Res
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1183/23120541.01390-2024,
  title = {Mepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two years.},
  author = {Canonica GW and  Bagnasco D and  Lee JK and  Chupp G and  Schleich F and  Oppenheimer JJ and  Zhang L and  Alfonso-Cristancho R and  Howarth P.},
  year = {2025},
  journal = {ERJ Open Res},
  doi = {10.1183/23120541.01390-2024},
  url = {https://doi.org/10.1183/23120541.01390-2024}
}

RIS

TY  - JOUR
TI  - Mepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two years.
AU  - Canonica GW
AU  -  Bagnasco D
AU  -  Lee JK
AU  -  Chupp G
AU  -  Schleich F
AU  -  Oppenheimer JJ
AU  -  Zhang L
AU  -  Alfonso-Cristancho R
AU  -  Howarth P.
PY  - 2025
JO  - ERJ Open Res
DO  - 10.1183/23120541.01390-2024
UR  - https://doi.org/10.1183/23120541.01390-2024
ER  -

APA

GW, C., D, B., JK, L., G, C., F, S., JJ, O., L, Z., R, A., & P., H. (2025). Mepolizumab in patients with severe asthma and blood eosinophil counts between 150 and 300 cells per µL: benefits at two years.. ERJ Open Res. https://doi.org/10.1183/23120541.01390-2024

Source records

europe-pmc · retrieved 2026-09-26T10:38:33.514Z
doaj · retrieved 2026-09-26T10:38:33.476Z